Literature DB >> 32381656

Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes.

Daniela Matei1,2,3, Kenneth P Nephew4,5,6.   

Abstract

Ovarian cancer is an aggressive epithelial tumor that remains a major cause of cancer morbidity and mortality in women. Epigenetic alterations including DNA methylation and histone modifications are being characterized in ovarian cancer and have been functionally linked to processes involved in tumor initiation, chemotherapy resistance, cancer stem cell survival, and tumor metastasis. The epigenetic traits of cancer cells and of associated tumor microenvironment components have been shown to promote an immunosuppressive tumor milieu. However, DNA methylation and histone modifications are reversible, and therapies targeting the epigenome have been implicated in potential reinvigoration of the antitumor immunity. In this review, we provide an overview specifically of DNA methylation and histone modifications as "clothes of the ovarian cancer genome" in relationship to their functional effects and highlight recent developments in the field. We also address the clinical implications of therapeutic strategies to remove or alter specific articles of genomic "clothing" and restore normal cellular function. As the clothes of the genome continue to be deciphered, we envision that the epigenome will become an important therapeutic target for cancer. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32381656      PMCID: PMC7501210          DOI: 10.1158/0008-5472.CAN-19-3837

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  112 in total

1.  BRCA1 interacts with components of the histone deacetylase complex.

Authors:  R I Yarden; L C Brody
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 2.  Epigenetics in ovarian cancer.

Authors:  Yanina Natanzon; Ellen L Goode; Julie M Cunningham
Journal:  Semin Cancer Biol       Date:  2017-08-03       Impact factor: 15.707

3.  A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.

Authors:  Fang Fang; Curt Balch; Jeanne Schilder; Timothy Breen; Shu Zhang; Changyu Shen; Lang Li; Carol Kulesavage; Anthony J Snyder; Kenneth P Nephew; Daniela E Matei
Journal:  Cancer       Date:  2010-09-01       Impact factor: 6.860

4.  The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.

Authors:  Andrew J Wilson; Matthew Stubbs; Phillip Liu; Bruce Ruggeri; Dineo Khabele
Journal:  Gynecol Oncol       Date:  2018-03-20       Impact factor: 5.482

5.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

Review 6.  Epigenetic Determinants of Cancer.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-09-01       Impact factor: 10.005

7.  Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells.

Authors:  N Chapman-Rothe; E Curry; C Zeller; D Liber; E Stronach; H Gabra; S Ghaem-Maghami; R Brown
Journal:  Oncogene       Date:  2012-11-05       Impact factor: 9.867

8.  A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.

Authors:  Amit M Oza; Ursula A Matulonis; Angeles Alvarez Secord; John Nemunaitis; Lynda D Roman; Sarah P Blagden; Susana Banerjee; William P McGuire; Sharad Ghamande; Michael J Birrer; Gini F Fleming; Merry Jennifer Markham; Hal W Hirte; Diane M Provencher; Bristi Basu; Rebecca Kristeleit; Deborah K Armstrong; Benjamin Schwartz; Patricia Braly; Geoff D Hall; Kenneth P Nephew; Simone Jueliger; Aram Oganesian; Sue Naim; Yong Hao; Harold Keer; Mohammad Azab; Daniela Matei
Journal:  Clin Cancer Res       Date:  2019-12-12       Impact factor: 12.531

9.  Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.

Authors:  James M Flanagan; Angela Wilson; Chail Koo; Nahal Masrour; John Gallon; Erick Loomis; Kirsty Flower; Charlotte Wilhelm-Benartzi; Alexander Hergovich; Paula Cunnea; Hani Gabra; Elena Ioana Braicu; Jalid Sehouli; Silvia Darb-Esfahani; Adriaan Vanderstichele; Ignace Vergote; Caroline Kreuzinger; Dan Cacsire Castillo-Tong; G Bea A Wisman; Els Mjj Berns; Nadeem Siddiqui; James Paul; Robert Brown
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

10.  Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.

Authors:  Michael R Savona; Kathryn Kolibaba; Paul Conkling; Edwin C Kingsley; Carlos Becerra; John C Morris; Robert M Rifkin; Eric Laille; Amy Kellerman; Stacey M Ukrainskyj; Qian Dong; Barry S Skikne
Journal:  Am J Hematol       Date:  2018-09-03       Impact factor: 10.047

View more
  18 in total

Review 1.  Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.

Authors:  Lana E Kandalaft; Denarda Dangaj Laniti; George Coukos
Journal:  Nat Rev Cancer       Date:  2022-09-15       Impact factor: 69.800

2.  Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A Is Mediated by Replication Protein A in Ovarian Cancer.

Authors:  Shruthi Sriramkumar; Timothy D Matthews; Ahmed H Ghobashi; Samuel A Miller; Pamela S VanderVere-Carozza; Katherine S Pawelczak; Kenneth P Nephew; John J Turchi; Heather M O'Hagan
Journal:  Mol Cancer Res       Date:  2020-08-14       Impact factor: 5.852

3.  LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer.

Authors:  Li-Yuan Feng; Yong-Zhi Huang; Wei Zhang; Li Li
Journal:  J Ovarian Res       Date:  2021-05-15       Impact factor: 4.234

4.  A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.

Authors:  Yao Peng; Hui Wang; Qi Huang; Jingjing Wu; Mingjun Zhang
Journal:  J Ovarian Res       Date:  2022-01-15       Impact factor: 4.234

5.  A SMYD3/ITGB6/TGFβ1 Positive Feedback Loop Promotes the Invasion and Adhesion of Ovarian Cancer Spheroids.

Authors:  Yahui Jiang; Tianyu Zhou; Yiwen Shi; Weiwei Feng; Tianjiao Lyu
Journal:  Front Oncol       Date:  2021-09-21       Impact factor: 6.244

Review 6.  Nicotinamide N-Methyltransferase: An Emerging Protagonist in Cancer Macro(r)evolution.

Authors:  Richard B Parsons; Paul D Facey
Journal:  Biomolecules       Date:  2021-09-28

Review 7.  Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives.

Authors:  Stanislas Quesada; Michel Fabbro; Jérôme Solassol
Journal:  Cancers (Basel)       Date:  2022-02-21       Impact factor: 6.639

8.  Prognostic Value and Therapeutic Potential of CBX Family Members in Ovarian Cancer.

Authors:  Kuan Hu; Lei Yao; Zhijie Xu; Yuanliang Yan; Juanni Li
Journal:  Front Cell Dev Biol       Date:  2022-01-27

9.  Comprehensive Landscape of Ovarian Cancer Immune Microenvironment Based on Integrated Multi-Omics Analysis.

Authors:  Jiacheng Shen; Tingwei Liu; Qiaoli Bei; Shaohua Xu
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

Review 10.  FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors.

Authors:  Tianshuo Yang; Long Ma; Haodong Hou; Feng Gao; Weijing Tao
Journal:  Front Oncol       Date:  2022-01-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.